Metastatic non-small cell lung cancer with BRCA2 mutation—a therapeutic challenge

Non-small cell lung cancer, specifically adenocarcinoma, is amenable to targeted therapy for genetic alterations. The role of BRCA mutations in pathogenesis and the efficacy of PARP inhibitors in these cases are still unclear. This case involves a 61-year-old male patient with a past history of Hodgkin's Lymphoma and a heavy smoking history who developed lung adenocarcinoma and was found to have a BRCA2 mutation. Following disease progression on first-line chemotherapy and a detailed case discussion in the multidisciplinary team meeting, second-line Olaparib was started, but the patient's condition worsened rapidly, and he died from the illness. This case highlights the fact that BRCA mutations, though less common, are a potential target that should be explored further. Further large-scale studies are crucial to understanding and improving treatment outcomes for patients with BRCA-mutated NSCLC.